In 2023, diabetes medicine sales in Canada were documented as a baseline. From 2024 onwards, the sales forecast indicates a consistent upward trend, with values rising from 107.4 to 151.6 in US dollars per capita by 2028. Year-on-year growth rates reveal steady increments, peaking at an estimated CAGR of 8.7% over the forecast period from 2024 to 2028. This sustained growth trajectory signals strong market dynamics and increasing demand for diabetes medications due to factors like rising prevalence and new drug innovations.
Future trends to watch include advancements in personalized medicine, increased market competition from generic drugs, and potential policy changes affecting pricing and reimbursement structures, which could significantly influence market dynamics.
